Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as BMS-986365, AR-LDD
CC-94676 · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| Part 1: Dose 1 | EXPERIMENTAL | - |
| Part 1: Dose 2 | EXPERIMENTAL | - |
| Part 1: Comparator 1 | ACTIVE_COMPARATOR | Enzalutamide or Abiraterone Acetate + Prednisone/Prednisolone |
| Part 1: Comparator 2 | ACTIVE_COMPARATOR | - |
| Part 2: Dose Selected | EXPERIMENTAL | - |
| Part 2: Comparator 1 | ACTIVE_COMPARATOR | Enzalutamide or Abiraterone Acetate + Prednisone/Prednisolone |
| Part 2: Comparator 2 | ACTIVE_COMPARATOR | - |
| Administration of CC-94676, CC1083611, and CC1083610 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| BMS-986365 | DRUG | Specified dose on specified days |
| Enzalutamide | DRUG | Specified dose on specified days |
| Abiraterone | DRUG | Specified dose on specified days |
| Docetaxel | DRUG | Specified dose on specified days |
| Predinsone/Prednisolone | DRUG | Specified dose on specified days |
| CC-94676 | DRUG | Specified dose on specified days |
| CC1083611 | DRUG | Specified dose on specified days |
| CC1083610 | DRUG | Specified dose on specified days |
Inclusion Criteria * Participants must have histologic or cytologic confirmation of adenocarcinoma of the prostate without small cell or neuro-endocrine features. * Participants must have current evidence of metastatic disease documented by either bone lesions on radionuclide bone scan and/or soft ...
CC-94676 is an investigational small molecule being studied for the treatment of prostatic neoplasms, specifically metastatic castration-resistant prostate cancer. It is currently in Phase 1 clinical development and is not yet approved by regulatory authorities.
CC-94676 is being developed by Bristol-Myers Squibb Company, a biopharmaceutical company listed on the New York Stock Exchange under the ticker symbol BMY.
CC-94676 is in Phase 1 clinical development. A Phase 1 study evaluating its safety and tolerability in participants with metastatic castration-resistant prostate cancer has been completed.
CC-94676 has one completed clinical trial, identified as NCT04428788. This Phase 1 study evaluated the safety and tolerability of CC-94676 in 131 male participants with metastatic castration-resistant prostate cancer in the United States.
CC-94676 is not FDA approved. It is an investigational drug that has completed a Phase 1 clinical trial, and it remains in clinical development for the treatment of metastatic castration-resistant prostate cancer.